CYP19A1 and neoplasm: Aromatase inhibitors (AIs), similar to the steroidal substrate analog exemestane (EXE), act to inhibit aromatase activity by blocking the biosynthesis of estrone and estradiol, thereby preventing estrogen-induced tumor cell growth (Miller, 1999; Campos, 2004; Santen et al., 2009).